Formulation and Development of Gastro-Retentive Floating Matrix Tablets of Zaltoprofen by Direct Compression Method

Abstract

Zaltoprofen inhibits the cyclooxygenase-2 (COX-2) enzyme, which is crucial for producing prostaglandins (like PGE2) that mediate pain, inflammation, and fever. It blocks the B2 bradykinin receptor-mediated signaling pathway in primary sensory neurons, effectively stopping bradykinin, a potent pain mediator, from activating pain signals. The Present study is aimed to develop a novel gastro retentive drug delivery system based on direct compression method for sustained delivery of active agent to improve the bioavailability, reduce the number of doses and to increase patient compliance. Gastro retentive floating tablets of Zaltoprofen were prepared by direct compression method using altered concentrations of Eudragit S100, Eudragit L100, Eudragit RSPO, MCC as Polymers. The prepared tablets of Zaltoprofen were evaluated for hardness, thickness, friability, weight variation, drug content uniformity, total floating time, in-vitro dissolution study, etc. in-vitro drug release of floating gastro retentive tablet of Zaltoprofen shown that the formulation F6 was found to be the best formulation as it releases 98% Lovastatin in a controlled manner for an extended period of time up to 10 hours. Prepared floating tablets of Zaltoprofen may prove to be a potential candidate for safe and effective controlled drug delivery over an extended period of time for gastro retentive drug delivery system.